Immunosuppressive AgentsCellCept (mycophenolate mofetil hydrochloride) Intravenous/Oral Suspension/Capsules/Tablets
Manufacturer: Hoffman La-Roche, Inc
Drug Approval Classification: Supplemental New Drug Application (Approval Date: 2/28/03)
Adverse Effects: The following statements were added to the "Adverse Reactions" section of the CellCept product labeling:
Patients receiving CellCept alone or as part of an immunosuppressive regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin.
All transplant patients are at increased risk of opportunistic infections. The risk increases with total immunosuppressive load.
Medscape Pharmacists. 2003;4(1) © 2003 Medscape
Cite this: April 2003 - Medscape - Apr 23, 2003.